AstraZeneca PLC has stolen a march on Sanofi with Forxiga being granted approval in Europe as the first oral add-on to insulin in type 1 diabetes patients a few days after its French rival failed to get a similar green light for Zynquista across the Atlantic.
Having secured a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in February,...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
